Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Divestments (2017 - 2022)

Integra Lifesciences Holdings (IART) has disclosed Divestments for 6 consecutive years, with $24.0 million as the latest value for Q3 2022.

  • Quarterly Divestments rose 1989.59% to $24.0 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $24.0 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $24.0 million for FY2022, 87.42% down from the prior year.
  • Divestments hit $24.0 million in Q3 2022 for Integra Lifesciences Holdings, up from -$1.3 million in the prior quarter.
  • In the past five years, Divestments ranged from a high of $191.7 million in Q1 2021 to a low of -$1.3 million in Q3 2021.
  • Historically, Divestments has averaged $55.0 million across 3 years, with a median of $14.8 million in 2018.
  • Biggest five-year swings in Divestments: surged 102.95% in 2018 and later surged 1989.59% in 2022.
  • Year by year, Divestments stood at $5.7 million in 2018, then crashed by 122.17% to -$1.3 million in 2021, then soared by 1989.59% to $24.0 million in 2022.
  • Business Quant data shows Divestments for IART at $24.0 million in Q3 2022, -$1.3 million in Q3 2021, and $191.7 million in Q1 2021.